Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
topic_facet:"Recruitment Status: Authorised-recruitment may be ongoing or finished"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=%22COVID%22&type=Subject
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=%22COVID%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=%22COVID%22&type=Subject
PubPharm (838)
1
Same as above : National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) - ENFORCE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. : Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase IIItrial. (REPAVID-22)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Same as above : National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) - ENFORCE
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. : Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase IIItrial. (REPAVID-22)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Short Title: Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)INSIGHT 012 : An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19 - Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
Immune response of VLA2001 Booster vaccine in adults who received mRNA COVID-19 vaccines, have been SARS-CoV-2 naturally infected or had a combination of both : OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCINES AND/ OR NATURAL SARS-COV-2 INFECTION. - VLA2001 booster after priming with mRNA COVID-19 vaccine and/or natural SARS-CoV-2 infection
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
This is a multicentre Phase II trial evaluating different booster strategies in individuals already vaccinated against SARS-CoV-2. This trial allows testing of different booster strategies for comparative assessment of their immune responses and safety against SARS-CoV-2 and its variants. This study tests whether a 4th vaccination dose is needed and determines the optimal booster vaccination schedule for further evaluation in a phase III trial. : An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a 4th homologous mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2 (EU-COVAT-2 BOOSTAVAC) - EU-COVAT-2 BOOSTAVAC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
A Study to Learn About a Repeat 5-Day Treatment with Nirmatrelvir/Ritonavir in People with Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment with Nirmatrelvir/Ritonavir : AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID-19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
A Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab in Pediatric Patients Hospitalized with COVID-19 : A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19 - N/A
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
A Multicentre, Open label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin versus Control in Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care (NEREIDA) : A Multicentre, Open label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin versus Control in Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care (NEREIDA)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[84]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Recruitment Status: Authorised-recruitment may be ongoing or finished
Medienart
838
Aufsätze
838
E-Artikel
838
E-Ressourcen
Zeitschriftentitel
838
WHO International Clinical Trials Registry Plat...
Thema
838
610
Recruitment Status: Authorised-recruitment may ...
838
Study Type: Interventional
400
Phase: Phase 2
256
Phase: Phase 3
138
Phase: Phase 4
44
Phase: Phase 1
38
Medical Condition: COVID-19;Therapeutic area: D...
14
Medical Condition: Acute respiratory distress s...
14
Medical Condition: Protection against COVID-19 ...
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 infection MedDRA ve...
12
Medical Condition: Coronavirus Disease 2019 (CO...
10
Medical Condition: COVID-19 MedDRA version: 23....
10
Medical Condition: COVID-19;Therapeutic area: D...
10
Medical Condition: Healthy Volunteers, with or ...
10
Medical Condition: Moderate to severe coronavir...
10
Medical Condition: moderate COVID-19 infection ...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
26
2023
180
2022
340
2021
292
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
816
Englisch
16
Unbestimmt
2
Französisch
2
Deutsch
2
Polnisch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...